Prof Simon Harrison
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
458 Scholarly works
12 Projects
HIGHLIGHTS
2026
Journal article
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma.
DOI: 10.1182/blood.20250320442026
Journal article
Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodies.
DOI: 10.1182/bloodadvances.20250195632026
Journal article
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups
DOI: 10.1016/j.clml.2025.12.0052026
Research grants (international)
Using Novel Biological Therapies to Target a Tumor-Specific Isoform of HER2 for the Treatment of Advanced Breast Cancer.
2021
Research grants (ARC, NHMRC, MRFF)
Studying the Origins, Maintenance and Resistance Mechanisms of Poor Risk Paediatric Leukaemia at Single Cell Resolution to Develop Novel Therapeutic Approaches
2020
Research Grant
ProTreat: An Adaptive and Rapid Implementation Trial of Novel Therapies to Prevent and Treat COVID19 Infection in High Risk Cancer Patients
2017
Journal article
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
DOI: 10.1182/blood-2017-06-788323
RECENT SCHOLARLY WORKS
2026
Journal article
New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts – A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)
DOI: 10.1016/j.clml.2025.10.0132026
Journal article
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial.
DOI: 10.1186/s41687-026-01034-z2026
Journal article
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
DOI: 10.1111/imj.703292026
Journal article
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
DOI: 10.1007/s12325-025-03479-y2026
Journal article
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
DOI: 10.1093/cid/ciaf4092026
Journal article
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
DOI: 10.1016/S1470-2045(25)00653-92026
Journal article
The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy
DOI: 10.1177/17562864251404464
RECENT PROJECTS
2024
Research grants (international)
Enhancing the 'Fitness' of Anti-Bcma CAR T Cells for Improved Efficacy in Multiple Myeloma